| Symbol | FULC |
|---|---|
| Name | FULCRUM THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 26 LANDSDOWNE STREET, CAMBRIDGE, Massachusetts, 02139, United States |
| Telephone | +1 617 651-8851 |
| Fax | — |
| — | |
| Website | https://www.fulcrumtx.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001680581 |
| Description | Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. It has developed a proprietary product engine that employs to identify and validate cellular drug targets that can modulate gene expression. Its product candidate, losmapimod, is a small molecule that was developed for the treatment of FSHD, a muscle-wasting disorder that leads to physical impairments and disability. Additional info from NASDAQ: |
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Read moreNew Form 3 - Fulcrum Therapeutics, Inc. <b>Filed:</b> 2026-05-01 <b>AccNo:</b> 0001193125-26-201437 <b>Size:</b> 17 KB
Read moreNew Form DEFA14A - Fulcrum Therapeutics, Inc. <b>Filed:</b> 2026-04-30 <b>AccNo:</b> 0001193125-26-197308 <b>Size:</b> 1 MB
Read moreNew Form ARS - Fulcrum Therapeutics, Inc. <b>Filed:</b> 2026-04-30 <b>AccNo:</b> 0001193125-26-197291 <b>Size:</b> 1 MB
Read more(30% Negative) FULCRUM THERAPEUTICS, INC. (FULC) Reports Q2 2026 Financial Results
Read moreFulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2026
Read moreFulcrum Therapeutics to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, April 27, 2026, at 8:00 a.m. ET
Read moreNew Form SCHEDULE 13G/A - Fulcrum Therapeutics, Inc. <b>Filed:</b> 2026-03-26 <b>AccNo:</b> 0000102909-26-001344 <b>Size:</b> 7 KB
Read moreMedicAlert Foundation, Sickle Cell Disease Association of America, Inc. (SCDAA), and Fulcrum Therapeutics Partner to Accelerate Emergency Department Access to Critical Care Information for People Living with Sickle Cell Disease
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07401823 | Open-Label Extension Study to Pioneer Study 6058-SCD-101 | Phase2 | Sickle Cell Disease | Enrolling_By_Invitation | 2026-03-30 | 2030-07-05 | ClinicalTrials.gov |
| NCT07431398 | Single-dose Pharmacokinetics of Pociredir in Participants With Sickle Cell Dise… | Phase1 | Sickle Cell Disease | Recruiting | 2025-12-13 | 2026-06-01 | ClinicalTrials.gov |
| NCT05397470 | Efficacy and Safety of Losmapimod in Treating Participants With Facioscapulohum… | Phase3 | Facioscapulohumeral Muscular Dystrophy (FSHD) | Terminated | 2022-06-16 | 2024-11-19 | ClinicalTrials.gov |
| NCT05169580 | Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Pociredir | Phase1 | Sickle Cell Disease | Completed | 2021-12-13 | 2026-01-20 | ClinicalTrials.gov |
| NCT05002231 | Relative Bioavailability and Food Effect Study of Losmapimod 15 mg Tablets | Phase1 | Healthy Adult Subjects | Completed | 2021-08-19 | 2021-10-22 | ClinicalTrials.gov |
| NCT04586985 | Safety, Tolerability and Pharmacokinetics of FTX-6058 | Phase1 | Healthy Adult Subjects | Completed | 2020-10-26 | 2022-11-15 | ClinicalTrials.gov |
| NCT04511819 | Losmapimod Safety and Efficacy in COVID-19 | Phase3 | COVID-19 | Terminated | 2020-08-28 | 2021-03-31 | ClinicalTrials.gov |
| NCT04264442 | Efficacy and Safety of Losmapimod in Treating Subjects With Facioscapulohumeral… | Phase2 | Facioscapulohumeral Muscular Dystrophy (FSHD) | Terminated | 2020-02-13 | 2024-11-07 | ClinicalTrials.gov |
| NCT04004000 | Evaluation of Safety, Tolerability, and Changes in Biomarker and Clinical Outco… | Phase2 | Facioscapulohumeral Muscular Dystrophy 1 | Terminated | 2019-08-23 | 2024-10-31 | ClinicalTrials.gov |
| NCT04003974 | Efficacy and Safety of Losmapimod in Subjects With Facioscapulohumeral Muscular… | Phase2 | Facioscapulohumeral Muscular Dystrophy (FSHD) | Completed | 2019-08-09 | 2021-01-28 | ClinicalTrials.gov |
| NCT00859716 | ACE393-103 Vaccination Challenge Study | Phase2 | Campylobacter Infection | Unknown | 2008-10-01 | 2009-07-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Placebo oral tablet | Other | Phase PHASE2 | Facioscapulohumeral Muscular Dystrophy (FSHD) | COMPLETED | NCT04003974 |
| Losmapimod oral tablet | Other | Phase PHASE2 | Facioscapulohumeral Muscular Dystrophy (FSHD) | COMPLETED | NCT04003974 |
| Placebo vaccine | Other | Phase PHASE2 | Campylobacter Infection | UNKNOWN | NCT00859716 |
| ACE393 | Other | Phase PHASE2 | Campylobacter Infection | UNKNOWN | NCT00859716 |
| Placebo vaccine | Other | Phase PHASE2 | Campylobacter Infection | UNKNOWN | NCT00859716 |
| ACE393 | Other | Phase PHASE2 | Campylobacter Infection | UNKNOWN | NCT00859716 |
| Losmapimod one 15 mg oral tablet | Other | Phase PHASE1 | Healthy Adult Subjects | COMPLETED | NCT05002231 |
| Losmapimod two 7.5 mg oral tablets | Other | Phase PHASE1 | Healthy Adult Subjects | COMPLETED | NCT05002231 |
| Losmapimod 15 mg oral tablet | Other | Phase PHASE1 | Healthy Adult Subjects | COMPLETED | NCT05002231 |
| FTX-6058 / Midazolam Syrup | Other | Phase PHASE1 | Healthy Adult Subjects | COMPLETED | NCT04586985 |
| FTX-6058 - Two Dosing Periods | Other | Phase PHASE1 | Healthy Adult Subjects | COMPLETED | NCT04586985 |
| FTX-6058/placebo oral capsule(s) | Other | Phase PHASE1 | Healthy Adult Subjects | COMPLETED | NCT04586985 |
| Placebo oral tablet | Other | Phase PHASE3 | COVID-19 | TERMINATED | NCT04511819 |
| Losmapimod oral tablet | Other | Phase PHASE3 | COVID-19 | TERMINATED | NCT04511819 |
| Losmapimod | Other | Phase PHASE2 | Facioscapulohumeral Muscular Dystrophy (FSHD) | TERMINATED | NCT04264442 |
| Placebo oral tablet | Other | Phase PHASE3 | Facioscapulohumeral Muscular Dystrophy (FSHD) | TERMINATED | NCT05397470 |
| Losmapimod | Other | Phase PHASE3 | Facioscapulohumeral Muscular Dystrophy (FSHD) | TERMINATED | NCT05397470 |
| Losmapimod | Other | Phase PHASE2 | Facioscapulohumeral Muscular Dystrophy 1 | TERMINATED | NCT04004000 |
| Pociredir oral capsule(s) | Other | Phase PHASE1 | Sickle Cell Disease | COMPLETED | NCT05169580 |
| Pociredir | Other | Phase PHASE1 | Sickle Cell Disease | RECRUITING | NCT07431398 |
| Pociredir | Other | Phase PHASE2 | Sickle Cell Disease | ENROLLING_BY_INVITATION | NCT07401823 |